GRIA2
MOLECULAR TARGETglutamate ionotropic receptor AMPA type subunit 2
GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GRIA2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | kainic acid | 3.81 | 44 |
| 2 | nbqx | 3.56 | 34 |
| 3 | cyclothiazide | 3.14 | 22 |
| 4 | Glutamic Acid | 3.00 | 19 |
| 5 | Glutamic Acid | 3.00 | 19 |
| 6 | s ampa | 3.00 | 19 |
| 7 | rs ampa | 3.00 | 19 |
| 8 | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2.94 | 18 |
| 9 | tezampanel anhydrous | 2.71 | 14 |
| 10 | Riluzole | 1.10 | 2 |
| 11 | aniracetam | 0.69 | 1 |
| 12 | Piracetam | 0.69 | 1 |
About GRIA2 as a Drug Target
GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented GRIA2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GRIA2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.